Thierry Hercend joins Covagen’s Scientific Advisory Board
Covagen announced that it has further strengthened its Scientific Advisory Board (SAB), which will be expanded by the addition of Dr. Thierry Hercend.
Dr. Thierry Hercend (MD, Ph.D.) has over 30 years of both academic and pharmaceutical experience in various therapeutic areas including oncology and inflammatory diseases. Since 2006, Dr. Thierry Hercend has been a Venture Partner at Edmond de Rothschild Investment Partners (EdRIP). He is the Chairman of the Supervisory Board of the biotechnology companies Cytomics Pharmaceuticals (Orsay, France) and Genticel (Innopole, France), and a member of the Scientific Advisory Board of Noxxon (Berlin, Germany). From 2002 until 2005, Dr. Hercend was Vice President in charge of the oncology therapeutic area at Aventis. From 1998 to 2002, he was Vice President of Research, Europe, at Vertex Pharmaceuticals (Cambridge, US). Previously, Dr. Hercend was Head of Research and Development for the Laboratory of Plasma Fractionation and Biotechnology (LFB) and was in various executive R&D positions with Roussel-Uclaf (Romainville, France).
Prior to joining the pharmaceutical industry, Dr. Hercend was Head of the Hemato-Immunology laboratories of the Gustave Roussy Cancer Institute (Villejuif, France), Director of the Inserm unit U333 dedicated to tumor immunology and a Professor of Immunology at the Medical Faculty of Paris XI University. He has authored more than 120 publications in oncology, auto-immune diseases and transplantation.
Other news from the department people
